Inhaled Furosemide & Dyspnea

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified November 2013 by McGill University
Sponsor:
Information provided by (Responsible Party):
Dennis Jensen, Ph.D., McGill University
ClinicalTrials.gov Identifier:
NCT01851980
First received: May 7, 2013
Last updated: November 28, 2013
Last verified: November 2013
  Purpose

"Dyspnea" refers to the awareness of breathing discomfort that is typically experienced during exercise in health and disease. In various participant populations, dyspnea is a predictor of disability and death; and contributes to exercise intolerance and an adverse health-related quality-of-life. It follows that alleviating dyspnea and improving exercise tolerance are among the principal goals of disease management. Nevertheless, the effective management of dyspnea and activity-limitation remains an elusive goal for many healthcare providers and current strategies aimed at reversing the underlying chronic disease are only partially successful in this regard. Thus, research aimed at identifying dyspnea-specific medications to complement existing therapies for the management of exertional symptoms is timely and clinically relevant. The purpose of this study is to test the hypothesis that single-dose inhalation of furosemide (a powerful loop diuretic) will improve the perception of dyspnea during strenuous exercise in healthy, young men in the presence of an external thoracic restriction. To this end, the investigators will compare the effects of inhaled 0.9% saline placebo and inhaled furosemide (80 mg) on detailed assessments of neural respiratory drive, ventilation, breathing pattern, dynamic operating lung volumes, contractile respiratory muscle function, cardio-metabolic function and dyspnea (sensory intensity and affective responses) during symptom-limited, high-intensity, constant-work-rate cycle exercise testing with and without external thoracic restriction in 28 healthy, men aged 20-40 years.


Condition Intervention Phase
Dyspnea
Other: CWS
Drug: Furosemide
Drug: Placebo
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Inhaled Furosemide on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction

Resource links provided by NLM:


Further study details as provided by McGill University:

Primary Outcome Measures:
  • Sensory intensity (Borg 0-10 scale) ratings of dyspnea at isotime [ Time Frame: Participants will be followed until all study visits are completed, an expected average of 3 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 28
Study Start Date: September 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CWS+Furosemide (80 mg)
Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (80 mg)
Other: CWS
Chest wall strapping to reduced vital capacity by 20% of its baseline value
Other Name: Chest wall strapping
Drug: Furosemide
Placebo Comparator: CWS+0.9% saline placebo
Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
Other: CWS
Chest wall strapping to reduced vital capacity by 20% of its baseline value
Other Name: Chest wall strapping
Drug: Placebo
0.9% saline
Active Comparator: No CWS+Furosemide (80 mg)
No chest wall strapping (unloaded control) + single-dose inhalation of furosemide (80 mg)
Drug: Furosemide
Placebo Comparator: No CWS+0.9% saline placebo
No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
Drug: Placebo
0.9% saline

  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male
  • Aged 20-40 years
  • FEV1 ≥80% predicted
  • FEV1/FVC >70%

Exclusion Criteria:

  • Current or ex-smoker
  • Body Mass Index <18.5 or >30 kg/m2
  • History of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction
  • Taking doctor prescribed medications
  • Allergy to latex
  • Allergy to lidocaine or its "caine" derivatives
  • Allergy to sulfa medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01851980

Contacts
Contact: Dennis Jensen, Ph.D. 514-398-4184 ext 0572 dennis.jensen@mcgill.ca

Locations
Canada, Quebec
Clinical Exercise & Respiratory Physiology Laboratory (CERPL) of McGill University
Montreal, Quebec, Canada, H2W1S4
Sponsors and Collaborators
McGill University
Investigators
Principal Investigator: Dennis Jensen, Ph.D. McGill University
  More Information

Additional Information:
No publications provided

Responsible Party: Dennis Jensen, Ph.D., Assistant Professor, McGill University
ClinicalTrials.gov Identifier: NCT01851980     History of Changes
Other Study ID Numbers: A02-M16-13B Furosemide
Study First Received: May 7, 2013
Last Updated: November 28, 2013
Health Authority: Canada: Ethics Review Committee

Keywords provided by McGill University:
Furosemide
Exercise

Additional relevant MeSH terms:
Dyspnea
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Furosemide
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 24, 2014